FLXN has been the subject of a number of other research reports. Wells Fargo & Co reissued a buy rating on shares of Flexion Therapeutics in a report on Wednesday, April 10th. Northland Securities reissued a buy rating and issued a $20.00 price objective on shares of Flexion Therapeutics in a report on Friday, March 1st. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Wednesday, February 13th. ValuEngine lowered shares of Flexion Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. Finally, BMO Capital Markets dropped their price objective on shares of Flexion Therapeutics from $36.00 to $34.00 and set an outperform rating for the company in a report on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $22.64.
Flexion Therapeutics stock opened at $10.63 on Friday. Flexion Therapeutics has a 52-week low of $9.90 and a 52-week high of $29.10. The firm has a market cap of $395.86 million, a PE ratio of -2.37 and a beta of 1.68. The company has a quick ratio of 7.58, a current ratio of 7.78 and a debt-to-equity ratio of 1.35.
In other news, insider Michael D. Clayman acquired 4,046 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average price of $12.36 per share, with a total value of $50,008.56. Following the completion of the acquisition, the insider now owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.59% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of FLXN. Point72 Asset Management L.P. acquired a new position in Flexion Therapeutics in the third quarter valued at about $23,768,000. Capital International Investors acquired a new position in Flexion Therapeutics in the third quarter valued at about $12,162,000. Selz Capital LLC acquired a new position in Flexion Therapeutics in the first quarter valued at about $3,619,000. D. E. Shaw & Co. Inc. lifted its position in Flexion Therapeutics by 516.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 250,402 shares of the specialty pharmaceutical company’s stock valued at $2,835,000 after buying an additional 209,809 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Flexion Therapeutics in the fourth quarter valued at about $849,000. 94.73% of the stock is currently owned by institutional investors.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
See Also: Closed-End Mutual Funds
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.